Ekso Bionics Holdings Inc.
| NASDAQ: EKSO | Healthcare / Medical Devices & Instruments / USA |
| 1.65 | +0.1100 | +7.14% | Vol 55.50K | 1Y Perf -46.71% |
| Mar 31st, 2023 16:00 DELAYED |
| BID | 1.55 | ASK | 1.70 | ||
| Open | 1.62 | Previous Close | 1.65 | ||
| Pre-Market | - | After-Market | 1.70 | ||
| - - | 0.05 3.03% |
| Target Price | 9.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 445.46 | Finscreener Ranking | ★★★+ 51.16 | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★★+ 52.91 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★ 43.98 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 32.29 | Earnings Rating | Neutral | |
| Market Cap | 22.01M | Earnings Date | 27th Apr 2023 | |
| Alpha | -0.03 | Standard Deviation | 0.30 | |
| Beta | 1.96 |
Today's Price Range 1.601.66 | 52W Range 1.032.95 | 5 Year PE Ratio Range -1.40-3.80 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 8.55% | ||
| 1 Month | 15.38% | ||
| 3 Months | 38.66% | ||
| 6 Months | 5.77% | ||
| 1 Year | -46.71% | ||
| 3 Years | -40.22% | ||
| 5 Years | -93.04% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -65.56 | |||
ROE last 12 Months | -43.63 | |||
ROA (5Y Avg) | -14.68 | |||
ROA last 12 Months | -32.80 | |||
ROC (5Y Avg) | -116.46 | |||
ROC last 12 Months | -39.86 | |||
Return on invested Capital Q | -12.96 | |||
Return on invested Capital Y | -6.99 | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.20 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.10 | ||||
| 0.62 | ||||
| 1.90 | ||||
| - | ||||
| -1.60 | ||||
| -0.88 | ||||
| 0.62 | ||||
| 3.08 | ||||
| -8 030 740.00 | ||||
| Forward PE | -2.81 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.10 | ||||
| 4.70 | ||||
| 0.04 | ||||
| 0.12 | ||||
| -116.20 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 48.60 | ||||
| -108.90 | ||||
| -105.90 | ||||
| -194.00 | ||||
| -94.39 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 9.36M | ||||
| 0.71 | ||||
| -5.38 | ||||
| 8.22 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | - | -0.24 | - |
| Q03 2022 | -0.24 | -0.33 | -37.50 |
| Q02 2022 | -0.24 | -0.23 | 4.17 |
| Q01 2022 | -0.41 | -0.36 | 12.20 |
| Q04 2021 | -0.25 | -0.23 | 8.00 |
| Q03 2021 | -0.25 | -0.17 | 32.00 |
| Q02 2021 | -0.25 | -0.26 | -4.00 |
| Q01 2021 | -0.24 | -0.34 | -41.67 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.22 | 0.00 | - |
| 12/2022 FY | -1.04 | 0.00 | - |
| 3/2023 QR | -0.16 | 0.00 | - |
| 12/2023 FY | -0.54 | 0.00 | - |
| Next Report Date | 27th Apr 2023 |
| Estimated EPS Next Report | -0.31 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 55.50K |
| Shares Outstanding | 13.34K |
| Shares Float | 12.77M |
| Trades Count | 282 |
| Dollar Volume | 90.35K |
| Avg. Volume | 23.88K |
| Avg. Weekly Volume | 18.41K |
| Avg. Monthly Volume | 20.89K |
| Avg. Quarterly Volume | 32.35K |
Ekso Bionics Holdings Inc. (NASDAQ: EKSO) stock closed at 1.65 per share at the end of the most recent trading day (a 7.14% change compared to the prior day closing price) with a volume of 55.50K shares and market capitalization of 22.01M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 68 people. Ekso Bionics Holdings Inc. CEO is Jack Peurach.
The one-year performance of Ekso Bionics Holdings Inc. stock is -46.71%, while year-to-date (YTD) performance is 38.66%. EKSO stock has a five-year performance of -93.04%. Its 52-week range is between 1.03 and 2.95, which gives EKSO stock a 52-week price range ratio of 32.29%
Ekso Bionics Holdings Inc. currently has a PE ratio of -1.10, a price-to-book (PB) ratio of 0.62, a price-to-sale (PS) ratio of 1.90, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.80%, a ROC of -39.86% and a ROE of -43.63%. The company’s profit margin is -94.39%, its EBITDA margin is -105.90%, and its revenue ttm is $9.36 Million , which makes it $0.71 revenue per share.
Of the last four earnings reports from Ekso Bionics Holdings Inc., there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.31 for the next earnings report. Ekso Bionics Holdings Inc.’s next earnings report date is 27th Apr 2023.
The consensus rating of Wall Street analysts for Ekso Bionics Holdings Inc. is Strong Buy (1), with a target price of $9, which is +445.46% compared to the current price. The earnings rating for Ekso Bionics Holdings Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Ekso Bionics Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Ekso Bionics Holdings Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.06, ATR14 : 0.08, CCI20 : 252.36, Chaikin Money Flow : -0.12, MACD : 0.00, Money Flow Index : 49.98, ROC : 16.20, RSI : 63.97, STOCH (14,3) : 96.88, STOCH RSI : 1.00, UO : 57.18, Williams %R : -3.13), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Ekso Bionics Holdings Inc. in the last 12-months were: Jason C. Jones (Sold 6 655 shares of value $14 590 ), Jerome Wong (Sold 4 269 shares of value $7 304 ), Scott G. Davis (Sold 9 040 shares of value $19 178 ), Steven Sherman (Option Excercise at a value of $0), Steven Sherman (Sold 92 400 shares of value $150 563 )
Ekso Bionics Holdings Inc.
Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are EksoHealth and EksoWorks. All of the company's operations are held in the United States. The EksoHealth segment which derives majority revenue designs, engineers, manufactures and sells exoskeletons for applications in the medical markets.
CEO: Jack Peurach
Telephone: +1 510 984-1761
Address: 1414 Harbour Way South, Richmond 94804, CA, US
Number of employees: 68
